Response assessment in neuro-oncology

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 50-56

  Quant, Eudocia C ^a   Wen, Patrick Y ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Brain metastases; High grade glioma; Low grade glioma; Macdonald criteria; Meningioma; Radiographic response; RANO criteria; Response assessment; Response criteria; Vestibular schwannomas

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; CORTICOSTEROID; TEMOZOLOMIDE; VASCULOTROPIN;

ACOUSTIC NEURINOMA; ARTICLE; BRAIN EDEMA; BRAIN METASTASIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; GLIOBLASTOMA; GLIOMA; HUMAN; MENINGIOMA; NERVOUS SYSTEM TUMOR; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VOLUME;

BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; GLIOMA; HUMANS; NERVOUS SYSTEM NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 79551558096     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0143-y     Document Type: Article

References (51)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society, Inc.; 2010.
2. Wen PY, Black PM, Loeffler JS: Metastatic brain cancer. In: Cancer: Principles and Practice of Oncology. Edited by DeVita V, Hellman S, Rosenberg SA. Philadelphia: Lippincott, Williams, & Wilkins; 2001:2655-2670.
3. Louis DN, Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer, B.W., and Kleihues, O.: The 2007 WHO classification of tumors of the central nervous system. Lyon, France: IARC Press; 2007.
4. PY Wen S Kesari 2008 Malignant gliomas in adults N Engl J Med 359 492 507 1:CAS:528:DC%2BD1cXpt1Sgsrw%3D 10.1056/NEJMra0708126 18669428
5. MJ van den Bent D Afra O de Witte, et al. 2005 Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial Lancet 366 985 990 10.1016/S0140-6736(05)67070-5 16168780 (Pubitemid 41323034)
6. FDA: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: US Department of Health and Human Services; 2007.
7. P Therasse S Arbuck E Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
8. EA Eisenhauer P Therasse J Bogaerts, et al. 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228 247 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 10.1016/j.ejca.2008.10.026 19097774
9. D Macdonald T Cascino SJ Schold J Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
10. AG Sorensen TT Batchelor PY Wen, et al. 2008 Response criteria for glioma Nat Clin Pract Oncol 5 634 644 10.1038/ncponc1204 18711427
11. • Henson JW, Ulmer S, Harris GJ: Brain tumor imaging in clinical trials. AJNR Am J Neuroradiol 2008, 29:419-424. This article offers an excellent overview of imaging in brain tumor trials.
12. van den Bent MJ, Vogelbaum MA, Wen PY et al: End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol 2009, 27:2905-2908. This article highlights limitations of Macdonald criteria.
13. PY Wen AD Norden J Drappatz E Quant 2010 Response assessment challenges in clinical trials of gliomas Curr Oncol Rep 12 68 75 10.1007/s11912-009-0078-3 20425610
14. Wen PY, Macdonald DR, Reardon DA et al: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972. This article, written by the RANO Working Group, provides recommendations for response assessment in high-grade gliomas.
15. MM Henegar CJ Moran DL Silbergeld 1996 Early postoperative magnetic resonance imaging following nonneoplastic cortical resection J Neurosurg 84 174 179 1:STN:280:DyaK287lt1ersg%3D%3D 10.3171/jns.1996.84.2.0174 8592218
16. S Ulmer TA Braga FG Barker 2nd, et al. 2006 Clinical and radiographic features of peritumoral infarction following resection of glioblastoma Neurology 67 1668 1670 1:STN:280:DC%2BD28nmslamug%3D%3D 10.1212/01.wnl.0000242894.21705. 3c 17101902 (Pubitemid 44747942)
17. Finn MA, Blumenthal DT, Salzman KL, Jensen RL: Transient postictal MRI changes in patients with brain tumors may mimic disease progression. Surg Neurol 2007, 67:246-250; discussion 250.
18. AJ Kumar NE Leeds GN Fuller, et al. 2000 Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment Radiology 217 377 384 1:STN:280:DC%2BD3crhtFeqsg%3D%3D 11058631
19. JG Cairncross DR Macdonald JH Pexman FJ Ives 1988 Steroid-induced CT changes in patients with recurrent malignant glioma Neurology 38 724 726 1:STN:280:DyaL1c3gt1Ciuw%3D%3D 3362369
20. CJ Watling DH Lee DR Macdonald JG Cairncross 1994 Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma J Clin Oncol 12 1886 1889 1:STN:280:DyaK2czmsFKgtw%3D%3D 8083712
21. AA Brandes E Franceschi A Tosoni, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844
22. ER Gerstner MB McNamara AD Norden, et al. 2009 Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression J Neurooncol 94 97 101 1:CAS:528:DC%2BD1MXotFWhsLs%3D 10.1007/s11060-009-9809-4 19221865
23. D Brandsma L Stalpers W Taal, et al. 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 10.1016/S1470-2045(08)70125-6 18452856 (Pubitemid 351597795)
24. AA Brandes A Tosoni F Spagnolli, et al. 2008 Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology Neuro Oncol 10 361 367 10.1215/15228517-2008-008 18401015
25. TT Batchelor DG Duda E di Tomaso, et al. 2010 Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma J Clin Oncol 28 2817 2823 1:CAS:528:DC%2BC3cXptFKmu78%3D 10.1200/JCO.2009.26.3988 20458050
26. JJ Vredenburgh A Desjardins JE Herndon 2nd, et al. 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440 17947719 (Pubitemid 350086473)
27. HS Friedman MD Prados PY Wen, et al. 2009 Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma J Clin Oncol 27 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
28. TN Kreisl L Kim K Moore, et al. 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 1:CAS:528:DC%2BD1MXjsVCjs7o%3D 10.1200/JCO.2008.16.3055 19114704
29. AD Norden GS Young K Setayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 1:CAS:528:DC%2BD1cXitlyqs7o%3D 10.1212/01.wnl.0000304121.57857.38 18316689
30. Narayana A, Raza S, Golfinos JG et al: Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival [abstract 13000]. Presented at the American Society of Clinical Oncology: Chicago, IL. May 30-June 3, 2008.
31. AD Norden J Drappatz PY Wen 2009 Antiangiogenic therapies for high-grade glioma Nat Rev Neurol 5 610 620 1:CAS:528:DC%2BD1MXhtlKhtLbE 10.1038/nrneurol.2009.159 19826401
32. RM Zuniga R Torcuator R Jain, et al. 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 329 336 1:CAS:528: DC%2BD1MXjvFemtQ%3D%3D 10.1007/s11060-008-9718-y 18953493
33. J Rubenstein J Kim T Ozawa, et al. 2000 Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption Neoplasia 2 306 314 1:CAS:528:DC%2BD3cXntVCjtb8%3D 10.1038/sj.neo.7900102 11005565
34. M Paez-Ribes E Allen J Hudock, et al. 2009 Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 220 231 1:CAS:528:DC%2BD1MXltFSmtbY%3D 10.1016/j.ccr.2009.01.027 19249680
35. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 1:CAS:528:DC%2BD1cXovV2lsrk%3D 10.1038/nrc2442 18650835
36. JF de Groot G Fuller AJ Kumar, et al. 2010 Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro Oncol 12 233 242 20167811
37. Gerstner E, Chen P-J, Wen P et al: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-Oncology, In press.
38. AF Eichler JS Loeffler 2007 Multidisciplinary management of brain metastases Oncologist 12 884 898 1:CAS:528:DC%2BD2sXpslerurs%3D 10.1634/theoncologist.12-7-884 17673619 (Pubitemid 47328231)
39. NU Lin LA Carey MC Liu, et al. 2008 Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 1993 1999 1:CAS:528:DC%2BD1cXlvFaqs7o%3D 10.1200/JCO.2007.12.3588 18421051
40. R Addeo C De Rosa V Faiola, et al. 2008 Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases Cancer 113 2524 2531 1:CAS:528:DC%2BD1cXhtlKru77F 10.1002/cncr.23859 18798231
41. FM Iwamoto AM Omuro JJ Raizer, et al. 2008 A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases J Neurooncol 87 85 90 1:CAS:528: DC%2BD1cXivFygtrc%3D 10.1007/s11060-007-9491-3 17987262
42. NU Lin V Dieras D Paul, et al. 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 1452 1459 1:CAS:528:DC%2BD1MXitVOktLo%3D 10.1158/1078-0432. CCR-08-1080 19228746
43. AR Asthagiri DM Parry JA Butman, et al. 2009 Neurofibromatosis type 2 Lancet 373 1974 1986 1:CAS:528:DC%2BD1MXmvFajt70%3D 10.1016/S0140-6736(09)60259- 2 19476995
44. Plotkin SR, Halpin C, Blakeley JO et al: Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol 2009, 93:61-77. This article provides recommendations for response criteria in NF2-related vestibular schwannoma studies.
45. DG Evans M Kalamarides K Hunter-Schaedle, et al. 2009 Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2 Clin Cancer Res 15 5032 5039 10.1158/1078-0432.CCR-08-3011 19671848
46. SR Plotkin AO Stemmer-Rachamimov FG Barker 2nd, et al. 2009 Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 N Engl J Med 361 358 367 1:CAS:528:DC%2BD1MXovFCrsLY%3D 10.1056/NEJMoa0902579 19587327
47. CBTRUS: Primary Brain Tumors in the United States, 2000-2004. Available at http://www.cbtrus.org/reports//2007-2008/2007report.pdf. Accessed December 1, 2008.
48. AD Norden J Drappatz PY Wen 2009 Advances in meningioma therapy Curr Neurol Neurosci Rep 9 231 240 1:CAS:528:DC%2BC3cXhtFeku7fO 10.1007/s11910-009- 0034-5 19348712
49. PY Wen WK Yung KR Lamborn, et al. 2009 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neuro Oncol 11 853 860 1:CAS:528:DC%2BC3cXotVOruw%3D%3D 10.1215/15228517-2009-010 19293394
50. AD Norden JJ Raizer LE Abrey, et al. 2010 Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma J Neurooncol 96 211 217 1:CAS:528:DC%2BC3cXpsVSjsw%3D%3D 10.1007/s11060-009-9948-7 19562255
51. LA Zeidman WJ Ankenbrandt H Du, et al. 2008 Growth rate of non-operated meningiomas J Neurol 255 891 895 1:STN:280:DC%2BD1crivVOmuw%3D%3D 10.1007/s00415-008-0801-2 18350353